Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Last trade$1.15
Day change-$0.15 (-11.58%)
Day range$0.949 – $1.29
Volume74,239
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.67M
Price / earnings
—
Price / book
-0.09×
Price / sales
0.01×
EV / sales
-0.05×
EV / EBITDA
1.6×
Profitability
Earnings per share
-$8.80
Return on assets
-15.46%
Return on equity
58.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.43×
Quick ratio
0.21×
Cash ratio
0.12×
Cash flow
Price / cash flow
1.17×
Price / free cash flow
—
Free cash flow
-$2.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRPL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$96.51M
$98.27M
$95.73M
$140.69M
$118.77M
$105.1M
$104.17M
$128.98M
Cost of revenue
$54.58M
$53.86M
$60.54M
$81.71M
$62.27M
$62.59M
$63.13M
$73.7M
Gross profit
$41.92M
$44.41M
$35.2M
$58.98M
$56.49M
$42.51M
$41.05M
$55.28M
Selling, general and administrative
$48.24M
$46.18M
$49.59M
$58.56M
$60.96M
$50.44M
$51.11M
$59.49M
Research and development
$2.36M
$2.49M
$2.45M
$2.61M
$2.37M
$2.18M
$2.45M
$2.39M
Total operating expenses
$51.7M
$48.66M
$52.04M
$61.16M
$68.62M
$56.75M
$55.53M
$62.97M
Operating income
-$9.77M
-$4.25M
-$16.84M
-$2.19M
-$12.13M
-$14.24M
-$14.48M
-$7.69M
Interest expense
-$8.09M
-$7.81M
-$8.22M
-$8.34M
-$8.2M
-$7.46M
-$4.76M
-$4.48M
Income before taxes
-$1.34M
-$3.21M
-$30.53M
-$3.17M
-$11.7M
-$17.32M
-$19.13M
-$8.62M
Income taxes
$76K
$32K
$47K
$59K
$53K
$54K
$41K
-$113K
Net income
-$1.42M
-$3.25M
-$30.58M
-$3.23M
-$11.75M
-$17.37M
-$19.17M
-$8.51M
Net income attributable to common shareholders
-$1.4M
-$3.23M
-$30.54M
-$3.21M
-$11.72M
-$17.35M
-$19.14M
-$8.48M
EBITDA
-$4.21M
$211K
-$12.42M
$2.22M
$2.94M
-$5.27M
-$7.47M
$1.31M
Basic earnings per share
-$0.32
-$0.74
-$7.00
-$0.74
-$2.71
-$4.01
-$4.50
-$1.97
Diluted earnings per share
-$0.33
-$0.74
-$7.00
-$0.74
-$2.71
-$4.01
-$4.50
-$1.96
Recent news
Company coverage with links to the original publishers.
The Hain Celestial Group reported a wider-than-expected adjusted loss of 7 cents per share in Q1 fiscal 2027, with net sales declining 29.3% to $260.3 million. While gross margins expanded 320 basis points to 22.8% due to the North American snacks divestiture, the company faces significant challenges including $586.1 million in debt maturing December 22, 2026, and uncertainty surrounding its planned International business sale to AURELIUS. Management has implemented cost-cutting measures and flagged substantial doubt about the company's ability to continue as a going concern.
Purple Innovation (PRPL) is drawing attention from options traders due to high implied volatility in its Jan. 15, 2027 $2.50 put options, suggesting expectations of significant price movement. However, the fundamental picture appears weak, with the company holding a Zacks Rank #2 (Buy) rating while analysts have reduced earnings estimates over the past 60 days, lowering consensus estimates from 19 cents to 17 cents per share for the current quarter.
Purple Innovation reported a quarterly loss of $2.41 per share, significantly worse than the consensus estimate of $0.72, representing a -234.72% earnings surprise. Revenue also missed expectations at $96.51 million versus consensus. The stock has declined 85.4% year-to-date, underperforming the S&P 500's 10.6% gain. Despite the poor results, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Clorox (CLX) delivered impressive Q1 fiscal 2027 results with adjusted EPS surging 82% year-over-year to $1.55 and net sales jumping 33% to $1.91B, both beating consensus estimates. However, gross margins contracted 130 basis points due to elevated commodity, manufacturing, and logistics costs. The company maintained full-year earnings guidance of $5.70-$6.00 per share but lowered gross margin expectations to 41.5%, with management expecting results near the lower end of guidance.
Colgate-Palmolive (CL) reported Q3 2026 earnings of 97 cents per share, up 7% year-over-year and beating consensus estimates. Net sales grew 4.6% to $5.37 billion with 3.6% organic sales growth driven by balanced volume (1.7%) and pricing (2%) gains. The company raised its 2026 Base Business earnings growth guidance to 5-7% and expects gross margin expansion. Regional performance was mixed, with Latin America and Asia Pacific showing strong growth while North America declined.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.